These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12955036)

  • 1. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry.
    Ogura H; Akiyama F; Kasumi F; Kazui T; Sakamoto G
    Breast Cancer; 2003; 10(3):234-40. PubMed ID: 12955036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2 testing in breast cancer using parallel tissue-based methods.
    Yaziji H; Goldstein LC; Barry TS; Werling R; Hwang H; Ellis GK; Gralow JR; Livingston RB; Gown AM
    JAMA; 2004 Apr; 291(16):1972-7. PubMed ID: 15113815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.
    Dowsett M; Bartlett J; Ellis IO; Salter J; Hills M; Mallon E; Watters AD; Cooke T; Paish C; Wencyk PM; Pinder SE
    J Pathol; 2003 Apr; 199(4):418-23. PubMed ID: 12635131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
    Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
    Giltnane JM; Molinaro A; Cheng H; Robinson A; Turbin D; Gelmon K; Huntsman D; Rimm DL
    Arch Pathol Lab Med; 2008 Oct; 132(10):1635-47. PubMed ID: 18834223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
    Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
    Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
    Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
    Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
    Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
    Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2 status determination in breast carcinomas. A practical approach.
    García-Caballero T; Menéndez MD; Vázquez-Boquete A; Gallego R; Forteza J; Fraga M
    Histol Histopathol; 2006 Mar; 21(3):227-36. PubMed ID: 16372244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?
    Pennacchia I; Vecchio FM; Carbone A; Arena V
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):31-5. PubMed ID: 25356940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
    Zhao J; Krishnamurti U; Zhang C; Meisel J; Wei Z; Suo A; Aneja R; Li Z; Li X
    Pathol Res Pract; 2020 Nov; 216(11):153155. PubMed ID: 32871536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent trends of HER-2 testing and trastuzumab therapy for breast cancer.
    Kurosumi M
    Breast Cancer; 2009; 16(4):284-7. PubMed ID: 19657709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardization of HER2 testing: results of an international proficiency-testing ring study.
    Dowsett M; Hanna WM; Kockx M; Penault-Llorca F; Rüschoff J; Gutjahr T; Habben K; van de Vijver MJ
    Mod Pathol; 2007 May; 20(5):584-91. PubMed ID: 17396141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
    Blank PR; Schwenkglenks M; Moch H; Szucs TD
    Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.